Get the Stockscreener App
13.15
0.19%
-0.025
After Hours:
13.15
Dyne Therapeutics Inc stock is traded at $13.15, with a volume of 2.03M.
It is down -0.19% in the last 24 hours and up +13.17% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$13.18
Open:
$13.11
24h Volume:
2.03M
Relative Volume:
0.68
Market Cap:
$1.87B
Revenue:
-
Net Income/Loss:
$-412.89M
P/E Ratio:
-3.4067
EPS:
-3.86
Net Cash Flow:
$-361.93M
1W Performance:
-7.52%
1M Performance:
+13.17%
6M Performance:
+6.39%
1Y Performance:
-60.24%
1-Day Range:
$13.07
$13.68
1-Week Range:
$12.62
$14.22
52-Week Range:
$6.36
$37.08
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
13.15 | 1.89B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
59,673 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Voleon Capital Management LP - MarketBeat
Graham Capital Management L.P. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 2,640 Shares - MarketBeat
Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $34.07 - MarketBeat
Exome Asset Management LLC Acquires Shares of 258,391 Dyne Therapeutics, Inc. $DYN - MarketBeat
Invesco Ltd. Has $693,000 Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating - Yahoo Finance
Dyne therapeutics CMO Kerr sells shares worth $59k By Investing.com - Investing.com Canada
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Trexquant Investment LP - MarketBeat
224,176 Shares in Dyne Therapeutics, Inc. $DYN Bought by PDT Partners LLC - MarketBeat
RA Capital Management L.P. Buys 3,333,248 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Frazier Life Sciences Management L.P. Makes New $15.10 Million Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Will Dyne Therapeutics Inc. outperform the market2025 Price Momentum & Free Growth Oriented Trading Recommendations - Newser
Trend analysis for Dyne Therapeutics Inc. this week2025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
Market reaction to Dyne Therapeutics Inc.’s recent newsInsider Selling & Technical Entry and Exit Tips - Newser
ADAR1 Capital Management LLC Buys Shares of 30,099 Dyne Therapeutics, Inc. $DYN - MarketBeat
Rafferty Asset Management LLC Sells 20,129 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. benefit from deglobalizationJuly 2025 Catalysts & Low Drawdown Momentum Ideas - خودرو بانک
Can Dyne Therapeutics Inc. be recession proofJuly 2025 Pullbacks & Intraday High Probability Alerts - خودرو بانک
Will Dyne Therapeutics Inc. stock recover after recent dropGap Down & Free Real-Time Volume Trigger Notifications - Newser
Dyne Therapeutics, Inc. $DYN Shares Bought by Armistice Capital LLC - MarketBeat
Chart based analysis of Dyne Therapeutics Inc. trendsMarket Movement Recap & Reliable Breakout Forecasts - Newser
Will Dyne Therapeutics Inc. benefit from government policyWeekly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Can Dyne Therapeutics Inc. navigate macro headwindsCPI Data & AI Based Buy and Sell Signals - خودرو بانک
What is the dividend yield of Dyne Therapeutics Inc.2025 Major Catalysts & Accurate Trade Setup Notifications - خودرو بانک
Is Dyne Therapeutics Inc. meeting your algorithmic filter criteria2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Dyne Therapeutics Inc. stock prediction for this week2025 Price Targets & AI Enhanced Trading Signals - Newser
Russell Investments Group Ltd. Has $710,000 Stock Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
How to use Fibonacci retracement on Dyne Therapeutics Inc.Earnings Overview Summary & Weekly Sector Rotation Insights - Newser
Will Dyne Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Risk Controlled Daily Plans - Newser
Custom watchlist performance reports with Dyne Therapeutics Inc.Dollar Strength & Low Drawdown Momentum Ideas - Newser
Is it time to cut losses on Dyne Therapeutics Inc.2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser
Intraday pattern recognizer results for Dyne Therapeutics Inc.July 2025 Short Interest & Weekly Breakout Watchlists - Newser
Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT - MSN
Can Dyne Therapeutics Inc. expand its profit marginsJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - خودرو بانک
Live market analysis of Dyne Therapeutics Inc.Weekly Trade Review & Risk Managed Investment Entry Signals - Newser
Key metrics from Dyne Therapeutics Inc.’s quarterly dataJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Newser
Should you hold or exit Dyne Therapeutics Inc. nowWeekly Stock Summary & Short-Term Trading Opportunity Alerts - Newser
Tick level data insight on Dyne Therapeutics Inc. volatilityLayoff News & Free Technical Confirmation Trade Alerts - Newser
Dyne Therapeutics, Inc. $DYN Shares Purchased by Siren L.L.C. - MarketBeat
Will Dyne Therapeutics Inc. continue its uptrendMarket Sentiment Report & High Accuracy Swing Entry Alerts - Newser
Pattern recognition hints at Dyne Therapeutics Inc. upsideQuarterly Market Summary & Expert Approved Momentum Ideas - Newser
Using fundamentals and technicals on Dyne Therapeutics Inc.July 2025 Sector Moves & Growth Focused Stock Reports - Newser
Is Dyne Therapeutics Inc. forming a double bottomProfit Target & Fast Momentum Stock Entry Tips - beatles.ru
Is Dyne Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - Newser
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):